12 results about "Lycorine" patented technology

The invention discloses a drug-loaded nanoparticle as well as a preparation method and application thereof. The drug-loaded nanoparticle can be used for treating triple negative breast cancer, and specifically comprises a magnetic nanoparticle, an active component loaded in the magnetic nanoparticle, and an erythrocyte membrane coating the magnetic nanoparticle, wherein the active ingredients are selected from one or more of piperlongumine, polyphyllin II, erianin, pseudolaric acid, 6-gingerol, ginkgetin, solasonine, cucurbitacine B and lycorine. In practical application, the drug-loaded nanoparticles have good biological safety, long circulation capability and high tumor retention capability, and can generate efficient killing and treatment effects on triple-negative breast cancer by inducing cell apoptosis.

The application provides a 1-substituted cinnamoyl-2-oxo lycorine compound, a preparation method and application thereof. The structure of the compound is shown in the following formula I: wherein the benzene ring has one or more R groups which are substituents on the benzene ring, and the R group is selected from hydrogen, C 1‑6 alkyl, C 1‑6 alkylalkoxy, halogen, halogenated C 1‑6 alkyl, halogenated C 1‑6 alkoxy, nitro and dioxo. The compound shows excellent antiviral effect, especially for herpes simplex virus type I (HSV-1), and the compound has better safety.

The application provides a LiCOMT gene for regulating synthesis of lycoris kingianus glycosides and application thereof, belongs to the technical field of plant genetic engineering, and the nucleotide sequence of the LiCOMT gene is shown as SEQ ID NO. 7, and the amino acid sequence of the encoded protein is shown as SEQ ID NO. 8; the application screens out a candidate gene LiCOMT significantly related to lycoris kingianus glycoside accumulation from lily bulb development period transcriptome data through weighted gene co-expression network analysis (WGCNA), and confirms that silencing the LiCOMT gene can reduce the content of lycoris kingianus glycoside A, lycoris kingianus glycoside B and lycoris kingianus glycoside F in lily bulbs by about 60%, 42% and 43% respectively by using a virus-induced gene silencing (VIGS) technique; and the application provides important gene resources and theoretical basis for lily secondary metabolism regulation and molecular breeding.

The invention provides lycorine-loaded functionalized methylacryloylated chitosan injection, gel, a preparation method and application, and relates to the field of medicines. The preparation method comprises the following steps: dropwise adding methacrylic anhydride into the chitosan-acetic acid solution, and reacting for 24 hours; dialyzing the reaction liquid, and performing freeze drying to obtain methacrylated chitosan CSMA; the preparation method comprises the following steps: dissolving CSMA in water, and stirring at room temperature for 12-24 hours until the solution is transparent to obtain a CSMA solution; adding the lycorine stock solution into the CSMA solution, and stirring for 30 minutes in a dark place; adding a photoinitiator, and stirring in a dark place until the photoinitiator is completely dissolved to obtain a CSMA-lycorine injection; and carrying out illumination curing on the injection to obtain the gel. The swelling property of the gel in the early stage can support the damaged centrum, CSMA is gradually degraded along with the recovery of the intervertebral disc in the middle and late stages, and the normal function and recovery of the intervertebral disc in the late stage cannot be influenced.

This invention discloses a lycorine-glycyrrhizic acid-copper nanohydrogel, its preparation method, and its applications. The invention provides a lycorine-glycyrrhizic acid-copper hydrogel composed of glycyrrhizic acid, lycorine, a copper ion compound, and water; the molar ratio of glycyrrhizic acid, lycorine, and the copper ion compound is 5-10:5-10:1-5; the concentration of glycyrrhizic acid is above 5 mM. This invention also protects the application of the lycorine-glycyrrhizic acid-copper hydrogel in the preparation of antitumor drugs. This invention aims to improve the dosage form of lycorine and enhance its efficacy and targeting, preparing lycorine into a novel nano-drug delivery dosage form. Compared with previously reported modified lycorine dosage forms, this dosage form exhibits stronger antitumor activity, better targeting, and stronger sustained-release effect.

The application discloses a preparation method and medical application of a lycoramine-glycyrrhizic acid self-assembly body. o The application discloses a preparation method and medical application of a lycoramine-glycyrrhizic acid self-assembly body. The application discloses a preparation method and medical application of a lycoramine-glycyrrhizic acid self-assembly body. The application discloses a preparation method and medical application of a lycoramine-glycyrrhizic acid self-assembly body. The application discloses a preparation method and medical application of a lycoramine-glycyrrhizic acid self-assembly body.

The application relates to a processing method of traditional Chinese medicinal materials and belongs to the field of deep processing of traditional Chinese medicinal materials. The application discloses a processing method for removing the toxicity of herba rhizomatosi, which comprises the following steps: (1) cleaning; (2) dampening: placing cleaned herba rhizomatosi underground stems in yellow wine for dampening; (3) steaming: placing the dampened herba rhizomatosi underground stems in a high-pressure steamer for steaming; (4) cooling: cooling the steamed herba rhizomatosi underground stems to room temperature; (5) pre-freezing: placing the cooled herba rhizomatosi underground stems in a pre-freezing cabinet for low-temperature freezing; (6) vacuum freezing drying: performing ultralow-temperature vacuum drying on the pre-frozen herba rhizomatosi underground stems in a vacuum freezing cabinet; and (7) warming: warming to room temperature in the freezing cabinet after the freezing drying is completed. The application adopts a modern ultrahigh-temperature steaming technology, which can deactivate the toxic component of herba rhizomatosi, i.e., lycoramine, on one hand, and shorten the steaming time and reduce the loss of the characteristic active component, i.e., herbarhizomatosin, in the steaming process on the other hand.

The application discloses a hydrogel microsphere for treating drug-resistant ovarian cancer and a preparation method thereof. The microsphere is composed of a chitosan-modified 3,5-dihydroxybenzyl acetate derivative and a lycorine N-demethylation derivative, a chemotherapeutic drug (paclitaxel / cisplatin), hyaluronic acid, glycerol, glutaraldehyde and a copper death mixture (dithiofrane-copper-carrier and quercetin nanocrystals). The microsphere is formed through a microfluidic technology and has the characteristics of multi-mechanism synergy (inhibition of drug-resistant genes + induction of copper death + chemotherapy), efficient targeting (chitosan-enhanced biocompatibility) and controllable slow release (hyaluronic acid-glutaraldehyde crosslinking). In vitro / in vivo experiments show that the tumor inhibition rate of the microsphere reaches 75% at the highest, the safety is good, the process is mature, and the microsphere is suitable for large-scale production, thereby providing an innovative solution for drug-resistant ovarian cancer.

The invention relates to the technical field of biological medicine, and particularly discloses an active factor spray for skin inflammatory and allergic pruritus. The composition is prepared from hyaluronic acid, lycorine N-demethylated derivative, hedyotis diffusa polysaccharide, purified water and exosome hybrid peptide according to a specific ratio. Wherein the exosome hybrid peptide is composed of plant exosome loaded blue copper peptide, palmitoyl pentapeptide-4 and FGF2 growth peptide, and an efficient targeted delivery system is formed. Through combination of multi-component compounding and a delivery technology, the anti-inflammatory, itching-relieving and skin barrier repairing effects are synergistically achieved. And a safer and more comprehensive non-hormone local treatment new choice is provided for the skin inflammatory and allergic pruritus.

The invention relates to application of lycorine and derivatives thereof in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, a drug compound library is screened by utilizing a per2- / -mutant zebrafish depression model, and the situation that 10 mu M of lycorine chloride can effectively rescue the depression-like phenotype of the per2- / -mutant zebrafish is found; the monomer shows remarkable treatment effects in a per2 gene knockout zebrafish depression model: (1) behavioral improvement: depression-like phenotypes such as per2- / -zebrafish exploration behavior reduction, social interaction defects and sleep-awakening rhythm disorder can be effectively reversed; (2) molecular mechanism regulation: restoring neurotransmitter steady state by down-regulating cortisol level and inflammation-related gene expression; lycorine chloride comes from plants, is easy to obtain and low in cost, and can be combined with existing western medicines in the market to treat depression, so that depression symptoms can be relieved.

The invention belongs to the technical field of medicines, and particularly discloses a preparation method and application of a near-infrared hemicyanine fluorescent probe Hcy-NEO-Leu for detecting bacterial leucine aminopeptidase. The research aims to develop a near-infrared fluorescent probe Hcy-NEO-Leu capable of responding to leucine aminopeptidase (LAP), a series of lycorine derivatives are screened, the influence of the lycorine derivatives on the activity of the leucine aminopeptidase and the influence of the lycorine derivatives on biological membrane formation are researched, and finally a compound LY-58 with the inhibition effect superior to that of an inhibitor ubenimex is successfully screened. The near-infrared fluorescent probe Hcy-NEO-Leu not only has high sensitivity, good water solubility and excellent biocompatibility, but also has a bacterium targeting capability. Due to the characteristics, the probe Hcy-NEO-Leu can achieve implant infection imaging in vitro and in vivo, and the probe Hcy-NEO-Leu has important significance on later surgical debridement and treatment. In addition, the probe has wide application prospects in the fields of inhibitor screening, in-vivo and in-vitro imaging and the like, and a new breakthrough is brought to research and clinical practice in the field of medicine.

The invention belongs to the technical field of nano materials, biological medicine and material chemistry, and discloses a magnetic heteropolyacid core-shell composite material for slowly releasing and delivering lycorine and methotrexate, a preparation method and application, and the composite material sequentially comprises gamma-Fe2O3, a SiO2 layer, SiO2-NH2, phosphotungstic acid, MOFs and 4-aminopyridine and folic acid molecules. The composite material integrates the advantages of all the components, has magnetic responsiveness, adjustable porosity and good biocompatibility, and provides a novel material platform for a multifunctional drug delivery system, for example, the composite material can be applied to anti-cancer drug delivery. The technical problems of poor biocompatibility, difficulty in functional group modification, limited slow release effect and the like of the existing metal organic framework material (MOFs) in a drug delivery system are solved.